Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An integrated modelling approach for targeted degradation: insights on optimization, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions
Sofia Guzzetti, Pablo Morentin Gutierrez
Journal of Pharmacokinetics and Pharmacodynamics (2023) Vol. 50, Iss. 5, pp. 327-349
Open Access | Times Cited: 10

Showing 10 citing articles:

Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization toward orally available bifunctional protein degraders
Giulia Apprato, Giulia Caron, Gauri Deshmukh, et al.
Expert Opinion on Drug Discovery (2025)
Closed Access | Times Cited: 1
PK/PD modeling of targeted protein degraders: Charting new waters and navigating the shallows
Robin Thomas Ulrich Haid, Andreas Reichel
Drug Discovery Today (2025), pp. 104311-104311
Open Access
Computational approaches to aid PROTAC drug discovery
Sohini Chakraborti, Kirsten McAulay
Elsevier eBooks (2025)
Closed Access
Rational Proteolysis Targeting Chimera Design Driven by Molecular Modeling and Machine Learning
Shuoyan Tan, Zhuo Chen, Ruiqiang Lu, et al.
Wiley Interdisciplinary Reviews Computational Molecular Science (2025) Vol. 15, Iss. 2
Closed Access
Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK/PD Modeling
Robin Thomas Ulrich Haid, Andreas Reichel
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 3, pp. 770-781
Open Access | Times Cited: 3
Unraveling the Mechanism of Epichaperome Modulation by Zelavespib: Biochemical Insights on Target Occupancy and Extended Residence Time at the Site of Action
Sahil Sharma, Suhasini Joshi, Teja Kalidindi, et al.
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2599-2599
Open Access | Times Cited: 4
Pharmacodynamic Models of Indirect Effects and Irreversible Inactivation with Turnover: Applicability to Mechanism-Based Modeling of Gene Silencing and Targeted Protein Degradation
Angelia F Wang, Vivaswath S. Ayyar
Journal of Pharmaceutical Sciences (2023) Vol. 113, Iss. 1, pp. 191-201
Closed Access | Times Cited: 4
High-throughput kinetics in drug discovery
Maria Filipa Pinto, Julija Sirina, Nicholas D. Holliday, et al.
SLAS DISCOVERY (2024) Vol. 29, Iss. 5, pp. 100170-100170
Open Access | Times Cited: 1
Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase‐targeted protein degrader BGB‐16673
Yue Wu, Bernd Meibohm, Taichang Zhang, et al.
British Journal of Pharmacology (2024)
Open Access | Times Cited: 1
Meeting report: DMPK optimisation strategies and quantitative translational PKPD frameworks to predict human PK and efficacious dose of targeted protein degraders
Caroline Rynn, Heide Marika Duevel
Xenobiotica (2024) Vol. 54, Iss. 9, pp. 776-780
Closed Access
Page 1

Scroll to top